In the bustling city of Adelaide, a remarkable story of scientific innovation and determination unfolds. Professor Cedric Bardy, a French-born researcher, has embarked on a mission to tackle some of the most devastating brain disorders, including childhood dementia, brain cancer, and Parkinson's disease. His approach? Growing 'mini brains' or 'brain organoids' in a lab, a groundbreaking technique that offers a glimmer of hope for finding effective treatments.
The Power of Brain Organoids
Bardy's journey began with a focus on Parkinson's, but a chance encounter with Megan Maack, whose children suffer from childhood dementia, shifted his path. With a $2.5 million grant from the Federal Government, Bardy and his team at the South Australian Health and Medical Research Institute (SAHMRI) set out to make a difference.
The concept is simple yet revolutionary: grow miniature brains from stem cells and use them as a testing ground for potential cures. By comparing brain organoids from children with dementia to those without, Bardy can identify 'clear differences' in the cells, offering a unique insight into the disease.
Unbiased Evaluation with Machine Learning
What makes Bardy's work truly fascinating is his use of machine learning and artificial intelligence. A specialized microscope captures thousands of images of the mini brains, which are then fed into an algorithm. This algorithm can distinguish between healthy brain cells and those affected by dementia, providing an unbiased evaluation of potential treatments.
"The machine has never been trained with drug versus no drug, so we can trick the program into thinking the cells come from a healthy kid, even though it didn't. That's proof of efficacy," Bardy explains. This innovative approach not only speeds up the analysis process but also ensures an unbiased assessment, a critical aspect when dealing with such complex diseases.
Overcoming Funding Challenges
However, Bardy's journey hasn't been without its challenges. The competitive research funding landscape in Australia has forced him to spend an inordinate amount of time writing grant applications, with a success rate of only 10%. To overcome this hurdle, Bardy decided to turn his research into a business, Brain Organoid Therapeutics.
"We're adding a new step that didn't exist before, and this is our mission - by adding a step, we can reduce the failure. There's always some risk, but if we can reduce that risk, that's huge," Bardy says.
By partnering with pharmaceutical giants, Bardy can offer his expertise in stem cell research, providing an additional layer of testing before drugs are trialed on humans. This not only saves money for the pharmaceutical companies but also reduces the risk of failure, a win-win situation.
A Global Perspective
Bardy's background is a testament to the global nature of scientific research. Having studied and worked in Paris, Sydney, and Montreal, he brings a unique perspective to his work. His fascination with the human memory, developed during his time in Canada, has driven his passion for brain research.
"I thought it was the most amazing thing ever," Bardy recalls.
With his innovative approach and global experience, Bardy is not only making a difference in the lives of children with dementia but also contributing to a broader understanding of brain disorders and their potential treatments.
Conclusion
Professor Cedric Bardy's work with brain organoids offers a glimpse into the future of medical research. By combining cutting-edge technology, machine learning, and a global perspective, he is tackling some of the most challenging brain disorders. His story serves as a reminder that innovation and perseverance can lead to groundbreaking discoveries, offering hope to those affected by these devastating diseases.
